Gene Genetic Technologies Ltd Says Plans Continue To Be Focussed On Concierge Medicine Groups And Gaining Coverage From US Payer System
Gene Genetic Technologies Ltd Says Plans Continue To Be Focussed On Concierge Medicine Groups And Gaining Coverage From US Payer System
基因遗传技术有限公司表示，计划继续将重点放在礼宾医疗团体和获得美国付款人系统的保险上
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates:
Genetic Technologies Limited(澳大利亚证券交易所股票代码：GTG，纳斯达克代码：GENE，“公司”，“GTG”，“GENE”)是健康、健康和严重疾病方面以指南为基础的基因组学检测的全球领先企业，该公司高兴地报告了美国战略业务的出色商业进展，最新情况如下：
Strategic Highlights:
战略要点：
Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives
Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions
Commercial evaluations underway at 10 US medical/family practices
Re-engagement with 1,600 previous geneType US customers
Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders...
与11个美国付款人团体积极接触，最初的目标名单为30个，覆盖数千万人的生活
与19家美国礼宾医疗诊所进行大批量定价...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。